
    
      This is a randomized open label clinical trial to evaluate Ertapenem administered
      subcutaneously is non-inferior to the same antibiotic intravenously to treat urinary tract
      infections in oncological palliative care patients.

      The study will be performed at the Palliative Care Unit (PCU) of the National Cancer
      Institute of Brazil Jos√© Alencar Gomes da Silva (INCA), a 56-bed hospital and the only public
      hospital for cancer palliative care located in the city of Rio de Janeiro, Brazil.

      A sample of 82 patients was estimated, considering the level of significance (alpha) of
      unilateral 2.5%, the power of the study (1-beta) of 80%, the non-inferiority limit of 4%, and
      success percentages in the groups control and experimental studies of 92% and 100%,
      respectively. Once the high mortality rate of the study site (about 60%, according to
      unpublished administrative information), it was decided to increase this number by 30% to
      compensate for possible losses, totaling 106 patients, 53 in each arm.
    
  